
May 12, 2026
Artera gets FDA clearance for AI breast cancer risk prediction tool
Artera has achieved FDA clearance for its AI-driven tool designed to predict the risk of distant metastases in specific breast cancer cases.This new technology, known as ArteraAI Breast, leverages histopathology images alongside clinical variables to categorize patients into low- and high-risk groups for developing advanced breast cancer. The FDA's clearance focuses on patients with early-stage, hormone receptor-positive, HER2-negative invasive breast cancer, a demographic that typically undergo









